Sage Therapeutics Inc (FRA:SG7)
€ 5.452 0.102 (1.91%) Market Cap: 325.18 Mil Enterprise Value: -211.07 Mil PE Ratio: 0 PB Ratio: 0.61 GF Score: 49/100

SAGE Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 10, 2021 / 04:30PM GMT
Release Date Price: €37.98 (-0.21%)
Matthew Kelsey Harrison
Morgan Stanley, Research Division - Executive Director

Good afternoon, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have Sage Therapeutics with us.

Quickly before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.

And with that, pleased to turn it over to Barry Greene, the CEO, to make some opening comments and then we'll jump into Q&A.

Barry E. Greene
Sage Therapeutics, Inc. - President, CEO & Director

Great. Thanks, Matthew, and especially thanks to Morgan Stanley for having us today. It really is an exciting time at Sage, and I'm thrilled with the substantial progress we've made so far this year, which is in line with the goals we laid out at the beginning of the year to expand and accelerate our pipeline

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot